These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28449182)

  • 1. Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer.
    Wang ZX; Li GX; Zhou ZW; Huang ZP; Wang F; Xu RH
    Br J Surg; 2017 Aug; 104(9):1226-1234. PubMed ID: 28449182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
    Wu Y; Wei ZW; He YL; Schwarz RE; Smith DD; Xia GK; Zhang CH
    World J Gastroenterol; 2013 Jun; 19(21):3309-15. PubMed ID: 23745033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
    Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
    Wang ZX; Yang XL; He MM; Wang F; Zhang DS; Li YH; Zhou ZW; Zhan YQ; Xu RH
    Medicine (Baltimore); 2016 Apr; 95(16):e3214. PubMed ID: 27100411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
    Chen S; Chen YB; Zhou ZW; Li W; Sun XW; Xu DZ; Li YF; Guan YX; Feng XY; Zhan YQ
    Am J Clin Oncol; 2011 Jun; 34(3):309-13. PubMed ID: 20838324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
    Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
    Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China.
    Zheng CH; Lu J; Huang CM; Li P; Xie JW; Wang JB; Lin JX
    Hepatogastroenterology; 2014 Oct; 61(135):1876-82. PubMed ID: 25713882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
    Zhang XL; Shi HJ; Cui SZ; Tang YQ; Ba MC
    Eur J Surg Oncol; 2011 Jun; 37(6):466-72. PubMed ID: 21414740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer.
    Han DS; Suh YS; Kong SH; Lee HJ; Choi Y; Aikou S; Sano T; Park BJ; Kim WH; Yang HK
    J Clin Oncol; 2012 Nov; 30(31):3834-40. PubMed ID: 23008291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer.
    Wang W; Sun Z; Deng JY; Qi XL; Feng XY; Fang C; Ma XH; Wang ZN; Liang H; Xu HM; Zhou ZW
    Cancer Commun (Lond); 2018 May; 38(1):23. PubMed ID: 29764518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].
    Ji J; Liang H; Zhan Y; Liu Y; He Y; Ye Y; Sun Y; Huang C; Yan M; Shi Y; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Feb; 17(2):133-8. PubMed ID: 24577767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer.
    Chipponi J; Huguier M; Pezet D; Basso N; Hay JM; Quandalle P; Jaeck D; Fagniez PL; Gainant A
    Am J Surg; 2004 Mar; 187(3):440-5. PubMed ID: 15006580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
    Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
    Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
    J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer.
    Xue Q; Wang XN; Deng JY; Zhang RP; Liang H
    World J Gastroenterol; 2013 Sep; 19(33):5551-6. PubMed ID: 24023500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.
    Kim SY; Yoon MJ; Park YI; Kim MJ; Nam BH; Park SR
    Gastric Cancer; 2018 May; 21(3):453-463. PubMed ID: 28828688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
    Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
    Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer.
    Sun P; Xiang JB; Chen ZY
    Br J Surg; 2009 Jan; 96(1):26-33. PubMed ID: 19016271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.